Skip to main content
SpringerLink
Log in

Intraperitoneal chemotherapy for ovarian carcinoma

  • Chapter
Ovarian Cancer

Part of the book series: Cancer Treatment and Research ((CTAR,volume 23))

Abstract

The first step in killing a tumor cell with a chemotherapeutic agent is to deliver the drug to the cell. Whether the cell is intrinsically sensitive or realtively resistant, the effect of the drug is proportional to the product of its concentration and the duration of exposure. In the case of tumors largely confined to extravascular cavities, such as ovarian carcinoma, there is a legitimate concern that injection of cytotoxic agents intravenously may not be the optimal way to get drug to the tumor. Following intravenous injection, most drugs have ready access to the well vascularized marrow and gut, but because of longer diffusional distances they may have much less access to intraperitoneal tumor. This is analogous to the problem of delivering drug to brain tumors that reside at least partially behind the blood-brain barrier [1]. A number of investigators have tried to improve drug delivery to the tumor by instilling cytotoxic agents directly into the peritoneal cavity, but early studies were done in a limited number of patients using small injection volumes and the results were not particularly exciting [2–4]. However, during the past five years there has been a resurgence of interest in using the intraperitoneal (i.p.) route, spurred initially by work performed at the National Cancer Institute which provided a solid pharmacologic rationale for this approach.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Levin VA, Patlak CS, Landahl MD: Heuristic modelling of drug delivery to malignant brain tumors. J Pharmacokinetics and Biopharmaceutics 8:257–296, 1980.

    Article  CAS  Google Scholar 

  2. Weisberger AS, Levine B, Storaasli JP: Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. JAMA 159:1704–1707, 1955.

    CAS  Google Scholar 

  3. Green TH: Hemisulfer mustard in the palliation of patients with metastatic ovarian carcinoma. Obstet Gynecol 13:383–393, 1959.

    Article  PubMed  Google Scholar 

  4. Kottmeier HL: Treatment of ovarian carcinomas with thiotepa. Clin Obstet Gynecol 11:428–438, 1968.

    PubMed  CAS  Google Scholar 

  5. Dedrick RL, Myers CE, Bungay PM,DeVita VT, Jr: Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treatment Rep 62:1–9, 1978.

    CAS  Google Scholar 

  6. Kraft AR, Tompkins RK, Jesseph JE: Peritoneal electrolyte absorption: analysis of portal, systemic venous and lymphatic transport. Surgery 64:148–153, 1968.

    PubMed  CAS  Google Scholar 

  7. Lukas G, Brindle SD, Greengard P: The route of absorption of intraperitoneally administered compounds. J Pharmacol Exp Ther 178:562–566, 1971.

    PubMed  CAS  Google Scholar 

  8. Speyer JL, Sugarbaker PH, Collins JM, Decrick RL, Klecker RW Jr, Myers CE: Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res 41:1916–1922, 1981.

    PubMed  CAS  Google Scholar 

  9. Chabner BA, Johns DG, Coleman CN, Drake JC, Evans WH: Purification and properties of cytidine deaminase from normal and leukemic granulocytes. J Clin Invest 53:922–931, 1974.

    Article  PubMed  CAS  Google Scholar 

  10. Howell SB, Chu BCF, Wung WE, Metha BM, Mendelsohn J: Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions. J Clin Invest 67:1161–1170, 1981.

    Article  PubMed  CAS  Google Scholar 

  11. Jones RB, Collins JM, Myers CE, Brooks AE, Hubbard SM, Balow JE, Brennan MR, Dedrick RL, DeVita VT: High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer. Cancer Res 41:55–59, 1981.

    PubMed  CAS  Google Scholar 

  12. Pfeifle CE, King ME, Howell SB: Pharmacokinetics and clinical efficacy of intraperitoneal cytarabine treatment of advanced ovarin cancer. Proc Am Soc Clin Oncol 2:150, 1983.

    Google Scholar 

  13. Bulkley GB: Washout of intraperitoneal xenon: effective peritoneal perfusion as an estimation of splanchnic blood flow. In: Granger DN, Bulkley GB (eds) Measurements of Blood Row: Applications to the Splanchnic Circulation. Williams and Wilkins, Baltimore, Chapter 24, pp 441–453, 1981.

    Google Scholar 

  14. Lockhart RD, Hamilton GF, Fyfe FW: Anatomy of the human body. J.B. Lippincott Company, Philadelphia, 1960.

    Google Scholar 

  15. Romanes GB: Editor, Cunningham’s Textbook of Anatomy. Oxford University Press, London 1964.

    Google Scholar 

  16. Leak LV, Rahil K: Permeability of the diaphragmatic mesothelium: the ultrastructural basis for ‘stomata’. Am J Anat 151:577–594, 1978.

    Article  Google Scholar 

  17. Bollman JL, Cain JC, Grindlay JH: Techniques for the collection of lymph from the liver, small intestine, or thoracic duct of the rat. J Lab Clin Med 33:1349–1352, 1948.

    PubMed  CAS  Google Scholar 

  18. Reininger EJ, Saperstein LA: Effect of digestion on distribution of blood flow in the rat. Science 126:1178–0000, 1957.

    Article  Google Scholar 

  19. Torres IJ, Litterst CL, Guarino AM: Transport of model compounds across the peritoneal membrane in the rat. Pharmacology 17:330–340, 1978.

    Article  PubMed  CAS  Google Scholar 

  20. Dedrick RL, Flessner MF, Collins JM, Schults JS: Is the Peritoneum a membrane? Am Soc Artificial Int Organs 5:1–8, 1982.

    Google Scholar 

  21. Nolph KD, Popovich RP, Ghods AJ, Twardowski: Determinants of low clearances of small solutes during peritoneal dialysis. Kid Int 13:117–123, 1978.

    Article  CAS  Google Scholar 

  22. Nolph KD: Short dialysis, middle molecules, and uremia. Ann Int Med 86:93–97, 1977.

    PubMed  CAS  Google Scholar 

  23. Maher JF: Principles of dialysis and dialysis of drugs. Am J Med 62:475–481, 1977.

    Article  PubMed  CAS  Google Scholar 

  24. Nolph KD: Peritoneal clearences. J Lab Clin Med 94:519–525, 1979.

    PubMed  CAS  Google Scholar 

  25. Maher JF: Peritoneal transport rates: Mechanisms, limitation and methods for augmentation. Kid Int 18:117–120, 1980.

    Google Scholar 

  26. Holcenberg J, Anderson T, Ritch P, Skibba J, Howser D, Ring B, Adams S, Helmswoth M: Intraperitoneal chemotherapy with melphalan plus glutaminase. Cancer Res 43:1381–1388, 1983.

    PubMed  CAS  Google Scholar 

  27. Burchenal JH, Kalaher K, Dew K, Lokys L, Gale G: Studies of cross-resistance, synergistic combinations and blocking of activity of platinum derivaties. Biochimie 60:961–965, 1978.

    Article  CAS  Google Scholar 

  28. LeRoy AF, Lutz RJ, Dedrick RL, Litterst CL, Guarino AM: Pharmacokinetic study of cis-dichlorodiammineplatinum (II) (DDP) in the beagle dog: thermodynamic and kinetic behavior of DDP in a biologic milieu. Cancer Treatment Rep 63:59–70, 1979.

    CAS  Google Scholar 

  29. Himmelstein KJ, Patton TF, Belt RJ, Taylor S, Repta AJ, Sternson LA: Clinical kinetics of intact cisplatin and some related species. Clin Pharmacol Ther 29:658–664, 1981.

    Article  PubMed  CAS  Google Scholar 

  30. Speyer JL, Collins JM, Dedrick RL, Brennan MF, Buckpitt AR, Londer H, DeVita VT Jr, Myers CE: Phase I pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res 40:567–672, 1980.

    PubMed  CAS  Google Scholar 

  31. Howell SB, Wung WE, Taetle R, Hussain F, Romine JS: Modulation of 5-fluorouracil toxicity by allopurinol in man. Cancer 48:1281–1289, 1981.

    Article  PubMed  CAS  Google Scholar 

  32. Slevin ML, Piall EM, Aherne GW, Johnston A, Lister TA: The pharmacokinetics of cytosine arabinoside in the plasma and cerebrospinal fluid during conventional and high dose therapy. Medical and Pediatric Oncology Supplement 1:157–168, 1982.

    Article  Google Scholar 

  33. Howell SB, Pfeifle CE, Wung WE, Olshen RA, Lucas WE, Yon JL, Green M: Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 97:845–851, 1982.

    PubMed  CAS  Google Scholar 

  34. Alberts DS, Chang SY, Chen H-SG, Moon TE, Evans TL, Furner RL, Himmelstein K, Gross JF: Kinetics of intravenous melphalan. Clin Pharmacol Ther 26:73–80, 1979.

    PubMed  CAS  Google Scholar 

  35. Pfeifle CE, Howell SB, Olshen RA, Wung WE: Intraperitoneal melphalan: A phase I study. Am Soc Clin Pharm Therap 33:223, 1983.

    Google Scholar 

  36. Greene RF, Collins JM, Jenkins JF, Speyer JL, Myers CE: Plasma pharmacokinetics of adriamycin and adriamycinol: Implications for the design of in vitro experiments and treatment protocols. Cancer Research 43:3417–3421, 1983.

    PubMed  CAS  Google Scholar 

  37. Ozols RF, Young RC, Speyer JL, Sugarbaker PH, Green R, Jenkins J, Myers CE: Phase I and pharmacological studies of adriamycin administered intraperitonelly to patients with ovarian cancer. Cancer 42:4265–4269, 1982.

    CAS  Google Scholar 

  38. Jones RB, Myers CE, Guarino AM, Dedrick RL, Hubbard SM, DeVita VT: High volume intraperitoneal chemotherapy (‘belly bath’) for ovarian cancer. Cancer Chemother Pharmocol 1:161–166, 1978.

    CAS  Google Scholar 

  39. Katz ME, Schwartz PE, Kapp DS, Luikart S: Epithelial carcinoma of the ovary: current strategies. Ann Int Med 95:98–111, 1981.

    PubMed  CAS  Google Scholar 

  40. Tully TE, Goldberg ME, Loken MK: The use of 99mTc-sulfur colloid to assess the distribution of 32P chromic phosphate. J Nucl Med 15:190–191, 1974.

    PubMed  CAS  Google Scholar 

  41. Taylor A Jr et al.: Loculation as a contraindication to intracacitary 32P chromic phosphate therapy. J Nucl Med 16:318–319, 1975.

    PubMed  Google Scholar 

  42. Vider M, Deland Fm, Maruyama Y: Loculation as a contraindication to intracavitary 32P chromic phosphate therapy. J Nucl Med 17:150–151, 1976.

    PubMed  CAS  Google Scholar 

  43. Rosenshein N, Blake D, Mclntyre PA, Parmley T, Natarajan TK, Dvornicky J, Nickoloff E: The effect of volume on the distribution of substances instilled into the peritoneal cavity. Gynecologic Oncology 6:106–110, 1978.

    Article  PubMed  CAS  Google Scholar 

  44. Dunnick NR, Jones RB, Doppman JL, Speyer J, Myers CE: Intraperitoneal contrast infusion for assessment of intraperitoneal fluid dynamics. AJR 133:221–223, 1979.

    PubMed  CAS  Google Scholar 

  45. West GW, Weichselbau R, Little JB: Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy. Cancer Res 40:3668, 1980.

    Google Scholar 

  46. Durand RE: Row cytometry studies of intracellular adriamycin in multicell spheroids in vitro. Cancer Res 41:3495–3498, 1981.

    PubMed  CAS  Google Scholar 

  47. Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myers CE, Young RC: Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res 39:3209–3214, 1979.

    PubMed  CAS  Google Scholar 

  48. Fenstermacher JD, Patlak CS, Blasberg RG: Transport of material between brain extracellular fluid, brain cells and blood. Federation Proceedings 33 (9): 2070–2074, 1974.

    PubMed  CAS  Google Scholar 

  49. Blasberg RG, Patlak C, Fenstermacher JD: Intrathecal chemotherapy: Brain tissue profiles after ventriculocisternal perfusion. J Pharmacology & Experimental Therapeutics 195(l):73–83, 1975.

    CAS  Google Scholar 

  50. Blasberg RG, Patlak CS, Shapiro WR: Distribution of methotrexate in the cerebrospinal fluid and brain after intraventricular administration. Cancer Treatment Reports 61:633–641, 1977.

    PubMed  CAS  Google Scholar 

  51. Collins JM, Dedrick RL, Flessner MF, Guarino AM: Concentration-dependent disappearance of fluorouracil from peritoneal fluid in the rat: Experimental observations and distributed modeling. J Pharma Sci 71(7): 735–738, 1982.

    Article  CAS  Google Scholar 

  52. Collins JM, Dedrick RL, King FG, Speyer JL, Myers CE: Non-linear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes. Clin Pharmacol Ther pp 235–246, 1980.

    Google Scholar 

  53. Howell SB, Pfeifle CE, Wung WE, Olshen RA: Intraperitoneal cisplatin with systemic thiosulfate protection. Cancer Res 43:1426–1431, 1983.

    PubMed  CAS  Google Scholar 

  54. Ostrowski MJ, Halsall GM: Intracavitary bleomycin in the management of malignant effusions: A multicenter study. Cancer Treat Rep 66:1903–1907, 1982.

    PubMed  CAS  Google Scholar 

  55. Alberts DS, Chen H-SC, Chang SY, Peng YM: The disposition of intraperitoneal bleomycin, melphalan, and vinblastine in cancer patients. Recent Results in Cancer Research 74:293–299, 1980.

    PubMed  CAS  Google Scholar 

  56. Alberts DS, Chen H-SG, Mayersohn M, Perrier D, Moon TE, Gross JF: Bleomycin pharmacokinetics in man. Cancer Chemother Pharmacol 2:127–132, 1979.

    Article  PubMed  CAS  Google Scholar 

  57. Speyer JL, Myers CE: The use of peritoneal dialysis for delivery of chemotherapy to intraperitoneal malignancies. Recent Results in Cancer Research 74:264–269, 1980.

    PubMed  CAS  Google Scholar 

  58. Ozols RF, Grotzinger KR, Fisher RI, Myers CE, Young RC: Kinetic characterization and response to chemotherapy in a transplantable murine ovarian cancer. Cancer Res 39:3202–3208, 1979.

    PubMed  CAS  Google Scholar 

  59. Schwartz HS: A fluorometric assay for daunomycin and adriamycin in animal tissues. Biochemical Medicine 7:396–404, 1973.

    Article  PubMed  CAS  Google Scholar 

  60. Donelli MG, Martini A, Colombo T, Bossi A, Garattini S: Heart levels of adriamycin in normal and tumor-bearing mice. Europ J Cancer 12:913–923, 1976.

    CAS  Google Scholar 

  61. Howell SB, Taetle R: Effect of sodium thiosulfate on cis-Dichlorodiammineplatinum (II) toxicity and antitumor activity in L1210 leukemia. Cancer Treat Rep 64(4–5):616–616, 1980.

    Google Scholar 

  62. Casper ES, Kelson DP, Alcock NW, Lewis JL, Jr: Ip cisplatin in patients with malignant ascites: Pharmacokinetic evaluation and comparison with the i.v. route, cancer Treat Rep 67(3): 235–238, 1983.

    PubMed  CAS  Google Scholar 

  63. Wasserman TH, Comis RL, Goldsmith M, et al.: Tabular analysis of the clinical chemotherapy of solid tumors. Cancer Chemother Rep 6(3):399–419, 1975.

    Google Scholar 

  64. Ho DH, Frei E3rd: Clinical pharmacology of 1-beta-D-arabinofuranosyl cytosine. Clin Pharmacol Ther 12:944–954, 1971.

    PubMed  CAS  Google Scholar 

  65. King ME, Pfeifle CE, Markman M, Howell SB: Cytarabine pharmacokinetics following intraperitoneal administration. Clin Pharmacol Ther 33:222, 1983.

    Google Scholar 

  66. Vistica DT, Von Hoff DD, Torain B: Uptake of melphalan by human ovarian carcinoma cells and its relationship to the amino acid content of ascitic fluid. Cancer Treat Rep 65(1–2): 157–161, 1981.

    PubMed  CAS  Google Scholar 

  67. Holcenberg J, Anderson T, Ritch P, Skibba J, Howser D, Ring B, Adams S, Helmsworth M: Intraperitoneal chemotherapy with melphalan plus glutaminase. Cancer Res 43:1381–1388, 1983.

    PubMed  CAS  Google Scholar 

  68. Gyves J, Ensminger W, Niederhuber J, Manuzak P, Van Harken D, Janis MA, Stetson P, Knutsen C, Doan K: Phase I study of intraperitoneal (IP) 5 day continuoua 5-FU infusion and bolus mitomycin C. Proc ASCO 1:15, 1982.

    Google Scholar 

  69. Gianni L, Jenkins JF, Greene RF, Lichter AS, Myers CE, Collins JM: Pharmacokinetics of the hypoxic radiosensitizers misonidazole and demethylmisonidazole after intraperitoneal administration in humans. Cancer Res 43:913–916, 1983.

    PubMed  CAS  Google Scholar 

  70. Stratford IJ, Adams GE, Horsman MR, Kandaiya S, Rajartnam S, Smith E, Williamson C: The interaction of misonidazole with radiation, chemotherapeutic agents, or heat. Cancer Clin Trials 3:231–236, 1980.

    PubMed  CAS  Google Scholar 

  71. Goldie JH, Coltman AJ: A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727–1733, 1979.

    PubMed  CAS  Google Scholar 

  72. Goldie JH, Coldman AJ, Gudauskas GA: Rationale for the use of alternating non-crossresistant chemotherapy. Cancer Treat Rep 66(3): 439–449, 1982.

    PubMed  CAS  Google Scholar 

  73. Young RC, Chabner BA, Hubbard SP, Fisher RI, Bender RA, Anderson T, Simon RM, Canellos GP, DeVita, VT: Advanced ovarian adenocarcinoma: A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med 299:1261–1266, 1978.

    Article  PubMed  CAS  Google Scholar 

  74. Gershenson DM, Wharton JT, Herson J, Edwards CL, Rutledge FN: Single-agent cis-Platinum therapy for advanced ovarian cancer. Obstet Gynecol 58(4): 487–496, 1981.

    PubMed  CAS  Google Scholar 

  75. Williams CJ, Mead B, Arnold A, Green J, Buchanan R, Whitehouse M: Chemotherapy of advanced ovarian carcinoma. Cancer 49:1778–1783, 1982.

    Article  PubMed  CAS  Google Scholar 

  76. Cohen CJ, Goldberg JD, Holland JF, Bruckner HW, Deppe G, Gusberg SB, Wallach RC, Kabakow B, Rodin J: Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO Stages III and IV) as measured by surgical end-staging (second-look operation). Am J Obstet Gynecol 145:955–967, 1983.

    PubMed  CAS  Google Scholar 

  77. Drewinko B, Green Catherine, Loo TL: Combination chemotherapy in vitro with cis-dichlorodiammineplatinum (II). Cancer Treat Rep 60(11): 1619–1625, 1976.

    PubMed  CAS  Google Scholar 

  78. Bergerat J-P, Green C, Drewinko B: Combination chemotherapy in vitro. IV. response of human colon carcinoma cells to combinations using cis-diamminedichloroplatinum. Cancer Biochem Biophy 3:173–180, 1979.

    CAS  Google Scholar 

  79. Bergerat J-P, Drewinko B, Corry P, Barlogie B, Ho DH: Synergistic lethal effect of cis-dichorodiammineplatinum and 1-Beta-D-arabinofuranosylcytosine. Cancer Res 41:25–30, 1981.

    PubMed  CAS  Google Scholar 

  80. Markman M, Green MR, Pfeifle CE, Lucas WE, Yon JL, Howell SB: Combination intracavitary chemotherapy in patients with stage III–IV ovarian carcinoma failing standard treatment regimens. Proc ASCO 2:147, 1983.

    Google Scholar 

  81. Vaughan WP, Burke PJ: Development of a cell kinetic approach to curative therapy of acute myelocytic leukemia in remission using the cell cycle-specific drug 1-beta-d-arabinofuranosylcytosine in a rat model. Cancer Res 43:2005–2009, 1983.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Maurie Markman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen B. Howell
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Internal Medicine Section of Hematology & Oncology, University of Arizona Health Sciences Center, Tucson, Arizona, USA

    David S. Alberts

  2. Department of Obstetrics & Gynecology, University of Arizona Health Sciences Center, Tucson, Arizona, USA

    Earl A. Surwit

Rights and permissions

Reprints and permissions

Copyright information

© 1985 Martinus Nijhoff Publishers, Boston

About this chapter

Cite this chapter

Markman, M., Howell, S.B. (1985). Intraperitoneal chemotherapy for ovarian carcinoma. In: Alberts, D.S., Surwit, E.A. (eds) Ovarian Cancer. Cancer Treatment and Research, vol 23. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2561-1_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-2561-1_9

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-9609-6

  • Online ISBN: 978-1-4613-2561-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation